A phase 2 trial of ZG005 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, active and no longer recruiting.
Study of ZG005 in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06927687 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 50 participants enrolled, started 2025-06-13 and due to reach its primary completion in 2027-05. Interventions recorded: ZG005 for Injection.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.